0002021578-24-000001.txt : 20240502 0002021578-24-000001.hdr.sgml : 20240502 20240501195410 ACCESSION NUMBER: 0002021578-24-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240501 EFFECTIVENESS DATE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Naegis Pharmaceuticals Inc. CENTRAL INDEX KEY: 0002021578 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-512157 FILM NUMBER: 24904732 BUSINESS ADDRESS: STREET 1: 999 WEST BROADWAY STREET 2: SUITE 720 CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: 604-235-1682 MAIL ADDRESS: STREET 1: 999 WEST BROADWAY STREET 2: SUITE 720 CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 D 1 primary_doc.xml X0708 D LIVE 0002021578 Naegis Pharmaceuticals Inc. 999 WEST BROADWAY SUITE 720 VANCOUVER A1 BRITISH COLUMBIA, CANADA V5Z 1K5 604-235-1682 BRITISH COLUMBIA, CANADA None None Corporation true Ian McBeath 999 West Broadway Suite 720 Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 1K5 Executive Officer Director David Burgoyne 999 West Broadway Suite 720 Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 1K5 Executive Officer Director Philip Davies 999 West Broadway Suite 720 Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 1K5 Director Michael Liggett 999 West Broadway Suite 720 Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 1K5 Director Cameron Groome 999 West Broadway Suite 720 Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 1K5 Director Julian Gangolli 999 West Broadway Suite 720 Vancouver A1 BRITISH COLUMBIA, CANADA V5Z 1K5 Director Other Decline to Disclose 06b false 2024-04-19 false true false 0 350812 350812 0 U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on April 19, 2024, which was CDN$1.3748 = USD$1.00. false 4 0 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Naegis Pharmaceuticals Inc. /s/ Ian McBeath Ian McBeath Chief Executive Officer 2024-04-26